La demanda judicial sobre el talco para bebés plantea otras preguntas

In English | El veredicto de unos $72 millones de un jurado contra Johnson & Johnson, por no haberles advertido a los consumidores acerca del posible riesgo de cáncer que presenta el talco en el polvo de talco de baño y para bebés ha planteado preguntas sobre la seguridad del uso de estos productos, especialmente como parte de la higiene femenina. Fotos: 9 cosas que debes desechar ahora mismo El jurado en San Luis le otorgó la indemnización a la familia …

Baby Powder Lawsuit Raises Questions About Talc

En español | A $72 million jury verdict against Johnson & Johnson for failing to warn consumers of a potential cancer risk from talc in baby and bath powder has raised questions about the safety of using these items, especially for feminine hygiene. Jurors in St. Louis awarded the money to the family of a woman who said her fatal ovarian cancer was due to using the company’s talc-based Baby Powder and Shower-to-Shower powder for decades. Enter to win a Volvo …

Johnson & Johnson to Take $4 Billion Hit

Recently I wrote about how Johnson & Johnson inappropriately marketed Risperdal to treat agitation, confusion and other symptoms in older patients with dementia. As if that’s not enough, the company’s now tentatively agreeing to a $4 billion – yes, that’s billion – settlement with thousands of patients for whom a company-made hip implant failed. As the New York Times described it this week, J & J’s Depuy Orthapaedics unit made and marketed its Articular Surface Replacement, an all-metal hip implant, to doctors …

Drug Company to Pay $2.2 Billion in Risperdal Settlement

We hear a lot about how older Americans have difficulties with their prescription medications. That makes it all the more disturbing when a pharmaceutical company takes advantage of them by promoting a drug as safe and effective for a certain condition – like, say, dementia – when in fact it may not be. According to the Justice Department, that’s what Johnson & Johnson did in marketing its antipsychotic drug Risperdal to older adults and other vulnerable patients. Now the company will …